Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Silence Therapeutics plc

Market Cap 260M 343M 302M 278M 488M 32.53B 496M 3.34B 1.29B 15.96B 1.29B 1.26B 55.47B P/E 2026 *
-11.6x
P/E 2027 * -11.5x
Enterprise Value 108M 142M 125M 115M 201M 13.44B 205M 1.38B 534M 6.59B 533M 521M 22.92B EV / Sales 2026 *
37.6x
EV / Sales 2027 * -8.26x
Free-Float
69.36%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 72 13/12/2025
Director of Finance/CFO 54 20/02/2022
Chief Tech/Sci/R&D Officer - 31/12/2020
Director TitleAgeSince
Director/Board Member 63 20/06/2018
Chairman 72 30/11/2019
Director/Board Member 54 17/12/2025
Change 5-day change 1-year change 3-year change Capi.($)
+2.96%+4.21%-8.16%-2.76% 43.24B
+2.23%+8.26%+323.35%+564.22% 35.25B
+1.59%+4.63%+7.23%+54.02% 30.22B
+2.07%-4.40%+10.38%-19.99% 28.01B
-4.75%-8.29%+3.90%+13.88% 24.08B
+4.64%+3.20% - - 14.16B
+3.91%+2.57%+53.41%+111.95% 13.01B
+2.77%+4.02%+9.61%+15.31% 12.7B
+0.13%+3.97%+101.73%+91.70% 12.54B
Average +1.73%-0.78%+62.68%+103.54% 23.69B
Weighted average by Cap. +1.65%-0.72%+69.04%+120.47%

Financials

2026 *2027 *
Net sales 2.86M 3.78M 3.32M 3.06M 5.36M 358M 5.45M 36.69M 14.2M 175M 14.17M 13.87M 610M 4.13M 5.45M 4.79M 4.41M 7.74M 516M 7.87M 52.96M 20.5M 253M 20.45M 20.01M 880M
Net income -49.12M -64.82M -56.94M -52.47M -92.02M -6.14B -93.57M -630M -244M -3.01B -243M -238M -10.47B -80.11M -106M -92.87M -85.57M -150M -10.01B -153M -1.03B -398M -4.91B -397M -388M -17.08B
Net Debt -153M -202M -177M -163M -286M -19.09B -291M -1.96B -758M -9.37B -756M -740M -32.55B -294M -388M -341M -314M -551M -36.79B -561M -3.78B -1.46B -18.05B -1.46B -1.43B -62.74B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!